|Title:||Successful living-donor liver transplant for fulminant hepatitis in a heart recipient||Authors:||PO-CHIH YANG
|Issue Date:||2015||Publisher:||Baskent University||Journal Volume:||13||Journal Issue:||4||Start page/Pages:||369-370||Source:||Experimental and Clinical Transplantation||Abstract:||
Reactivation of hepatitis B virus replication is a known complication of immunosuppressive therapy, which can lead to hepatocellular injury, liver failure, and death. In this report, we describe the case of a 44-year-old man with chronic hepatitis B and a dilated cardiomyopathy status after a heart transplant. Reactivation of the patient’s hepatitis B virus occurred 4 months after the heart transplant. Despite prompt administration of antiviral therapy, he developed fulminant hepatitis with hepatic encephalopathy. A successful living-related liver transplant was performed 7 months after the heart transplant. The patient was followed up for 1 year, and during that time was free of hepatitis B virus. We suggest that routine antiviral therapy should be administered to patients with chronic hepatitis B receiving immunosuppressive therapy. ? Ba?kent University 2015 Printed in Turkey. All Rights Reserved.
|ISSN:||1304-0855||DOI:||10.6002/ect.2014.0030||SDG/Keyword:||alanine aminotransferase; aspartate aminotransferase; bilirubin; entecavir; hepatitis B antibody; prednisolone; tacrolimus; virus DNA; antivirus agent; immunosuppressive agent; acute hepatitis; adult; alanine aminotransferase blood level; Article; aspartate aminotransferase blood level; case report; congestive cardiomyopathy; disease course; follow up; graft recipient; heart function; heart transplantation; hepatic encephalopathy; hepatitis B; Hepatitis B virus; human; immunosuppressive treatment; liver failure; liver function; liver graft; living donor; male; postoperative period; urinalysis; virus load; weakness; adverse effects; complication; drug effects; heart transplantation; Hepatitis B, Chronic; immunocompromised patient; immunology; Liver Failure, Acute; liver transplantation; pathogenicity; procedures; treatment outcome; virology; virus activation; Adult; Antiviral Agents; Heart Transplantation; Hepatic Encephalopathy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Failure, Acute; Liver Transplantation; Living Donors; Male; Treatment Outcome; Virus Activation
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.